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Abstract A series of truncated dystrophin cDNAs (3.1^4.2 kbp)
containing only three, three, two or one rod repeats with hinge 1
and 4 (named vDysAX2, AX11, AH3, M3, respectively) or no
rod repeat retaining either hinge 1 or 4 (named vDysH1, H4,
respectively) were constructed. These cDNAs were introduced
into skeletal muscle of adult mdx mice using the adenovirus
vector with a strong CAG promoter. vDysAX2, AX11, AH3 and
vDysM3 expressed themselves successfully and recovered
dystrophin-associated proteins effectively. Especially 3.7 kbp
cDNA for vDysM3 offers the possibility of an approach utilizing
newly developed virus vectors, such as an adeno-associated virus
vector, toward gene therapy of Duchenne muscular dystrophy.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Duchenne muscular dystrophy (DMD) is an X-linked, le-
thal disorder of skeletal muscle caused by a defect in the
dystrophin gene. Progressive muscle weakness, cardiomyo-
pathy and early death characterize the disease. Epidemiolog-
ical studies have estimated its prevalence to be approximately
1 in 3500 newborn males, one-third of these cases being spo-
radic [1]. Currently, there is no e¡ective treatment for the
disease, but the relatively new ¢eld of gene therapy o¡ers
promising possibilities.
The native dystrophin gene measures 2.4 Mbp, while the
full-length dystrophin cDNA is about 14 kbp [2]. The gene
product, dystrophin, is a 427 kDa cytoskeletal protein that is
situated at the inner surface of the sarcolemma [3,4]. From its
position on the sarcolemma, dystrophin uses its N-terminal
domain to anchor actin ¢laments [5] and its cysteine-rich
and C-terminal domains to bind the integral and peripheral
membrane proteins and glycoproteins called dystrophin-asso-
ciated proteins (DAPs) [6]. It now seems clear that dystrophin
stabilizes the sarcolemma against contraction stress by linking
to the cytoskeleton [7]. Dystrophin’s rod domain, which ac-
counts for 76% of the molecule, mainly consists of 24 triple-
helical repeats and four hinge segments [8]. Although the role
of the rod domain is not fully understood, it has been shown
that a large omission in this domain results in a mild form of
dystrophy, Becker muscular dystrophy (BMD) [9]. ‘Mini-dys-
trophin’, isolated from a benign BMD patient, largely lacks
the central region of this repetitive domain; this includes
exons 17^48 (nucleotide positions 2201^7306), resulting in a
total of eight rod repeats with three hinge segments [10].
As an initial step toward gene therapy of DMD, researchers
have ¢rst employed the 6.3 kbp mini-dystrophin cDNA, be-
cause it is small enough to accommodate an E1-substitution-
type adenovirus (Ad) vector. The mini-dystrophin is success-
fully expressed in dystrophic mdx mice, especially when the
Ad construct is injected during the neonatal period [11^14]. In
addition, mouse transgenic studies have shown that the phe-
notypes of muscular dystrophy dramatically improved in mdx
mice carrying the mini-dystrophin gene [15,16]. It is notewor-
thy that these studies utilizing mini-dystrophin cDNA and
clinical data from a series of BMD patients [9] show the
possibility that long-period expression of dystrophin deleted
for a large part of the rod domain would maintain the cyto-
skeleton-sarcolemma linkage and prevent the dystrophic
change in dystrophin-de¢cient muscle.
However, when Ad is injected into adult mdx mice, an
immunological reaction to the Ad vector prevents long-lasting
expression of the dystrophin gene [14], indicating that a new
generation of Ad vector or a new virus vector is required.
Newly developed virus vectors, which are available in gene
transfer to skeletal muscle, have a limitation in the size of
the foreign gene. For example, adeno-associated virus
(AAV) vector allows an insertion of up to 4.6 kbp of exoge-
nous DNA [17]. Thus, truncation of dystrophin to a small size
would make it possible to employ a wider spectrum of virus
vectors.
Based on these observations, we designed a series of trun-
cated dystrophins with consecutive deletions in the rod do-
main, and examined their e¡ects on the expression of dystro-
phin and DAPs at the sarcolemma after Ad-mediated gene
transfer into skeletal muscles of mdx mice. Here we report
that truncated dystrophins bearing one to three rod repeats
and two hinge segments can e¡ectively accumulate at the sar-
colemma and recover DAPs, and 3.7 kbp cDNA for a trun-
cated dystrophin, which has only one rod repeat, can be a
good candidate to be inserted into AAV vectors.
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2. Materials and methods
2.1. Construction of truncated dystrophin cDNAs
We constructed a series of truncated dystrophin cDNAs with vary-
ing sizes of the rod domain (Fig. 1A). A 6.3 kbp NotI/SalI fragment
from human mini-dystrophin cDNA [18] was cloned into the NotI/
SalI sites of pBluescriptII(SK) (Stratagene), generating pBSBMD.
Four plasmids including cDNA of truncated dystrophin (vDys),
named AX2, AX11, AH3, and M3, were generated as follows. The
sequences of the primers and other oligonucleotides used in the con-
struction of the cDNAs are shown in Table 1. The PCR product
which was ampli¢ed with pBSBMD as the template and primers
F1/R1 or F2/R2 was digested with A£II/XhoI and inserted into the
A£II/XhoI sites of pBSBMD, generating pBSvDysAX2 and pBSv-
DysAX11, respectively. The PCR product ampli¢ed with pBSBMD
as the template and primers F4/R4 was digested with MunI/HindIII
and inserted into the MunI/HindIII sites of pBSBMD, generating
pBSvDysM3. A fragment that was formed by annealing oligonucleo-
tides, F3/R3, was used to link between the A£II and HindIII sites of
pBSBMD, generating pBSvDysAH3.
Two other plasmids including cDNA for vDysH1 and vDysH4
were generated from pBSvDysM3 (Fig. 1A). pBSvDysM3 was di-
gested with ApaI, then blunted and self-ligated to remove one of
the EcoO109I sites. The PCR product ampli¢ed using pBSvDysM3
as the template and primers F5/R5 was digested with EcoT22I/
EcoO109I and inserted into the EcoT22I/EcoO109I sites of the result-
ing plasmid, generating pBSvDysH1. To generate pBSvDysH4, two
PCR reactions were independently accomplished using pBSvDysM3
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Fig. 1. Construction of truncated dystrophin cDNAs with varying numbers of rod repeats. A: Diagram of human full-length dystrophin, mini-
dystrophin [10,18], and newly generated truncated dystrophin cDNAs. To construct vDysAX2, vDysAX11, vDysAH3, and vDysM3, the cen-
tral rod domain in the mini-dystrophin cDNA was digested with the restriction enzymes indicated on the right of each construct. Both of the
resulting ends were linked together by a PCR-ampli¢ed fragment or synthetic DNA fragment to reconstruct the rod repeat structure (for de-
tails, see Section 2). To construct vDysH1 and vDysH4, vDysM3 was digested with the restriction enzymes indicated and both ends were li-
gated using PCR-ampli¢ed fragments. The dotted line indicates the junction. The sizes of the cDNAs and the deduced molecular weights of
truncated dystrophins are indicated. The actin-binding domain is illustrated by dotted boxes, the rod domain by open boxes (each repeat de-
picted by a box), the cysteine-rich domain by hatched boxes and the C-terminal domain by shaded boxes. Black boxes indicate hinges. The
hinges are numbered according to the description by Koenig and Kunkel [8]. B: Amino acid sequences of the reconstructed rod repeat in vDy-
sAX2 (AX2), vDysAX11 (AX11), vDysAH3 (AH3) and vDysM3 (M3). Vertical bars indicate the positions of junctions. Triangles and dashes
indicate the positions of gaps and deletions to optimize the alignment of rod repeats [8]. CS 1 and CS 2 show consensus sequences from 24 re-
peats in dystrophin [8]. CS 1 indicates amino acids found in at least eight repeats and CS 2 shows amino acids appearing in 5, 6, or 7 repeats
among the 24. C: Amino acid sequences of vDysH1 (H1) and vDysH4 (H4) at the area of ligation. In vDysH1, hinge 1 is directly connected
to the cysteine-rich domain. In vDysH4, the actin-binding domain is connected to hinge 4. Tyrosine (T), marked with an asterisk, in hinge 1
was found to be substituted to alanine (A) in a family with X-linked dilated cardiomyopathy in North America [33]. The dashed line below
hinge 4 indicates the WW domain; the most conserved amino acids in the WW domain are underlined [31].
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as the template and primers F5/R6 or F6/R7. A mixture of two re-
sulting PCR products was used as the template for the second PCR
reaction with primers F5/R7. The second PCR product was digested
with EcoRV and was inserted between two EcoRV sites of
pBSvDysM3. The amino acid sequence of the linked regions is shown
in Fig. 1B,C.
2.2. Generation of recombinant adenoviruses expressing truncated
dystrophin
E1-substitution-type recombinant Ad vectors expressing each trun-
cated dystrophin were generated by the COS-TPC method [19].
Brie£y, each truncated dystrophin cDNA, vDysAX2, AX11, AH3,
M3, H1 or H4, was inserted into the CAG expression unit, which
has proven to have strong expression in vitro [20] and in vivo [21],
in the cassette cosmid pAxCAwt [22]. Each recombinant Ad was
generated by homologous recombination in 293 cells between the
resulting cosmid and the DNA-terminal protein complex of Ad5 dlx
[19,23]. The obtained recombinant Ad vectors, designated Ax-
CAvDys, were propagated, puri¢ed and titrated as described [24].
Each AxCAvDys was stored in phosphate-bu¡ered saline (PBS), con-
taining 10% glycerol, at 380‡C.
2.3. Gene transfer into cultured myoblasts and Western blot analysis
A subclone of C2C12 myoblasts [25] (approximately 1.0U105) was
plated and incubated for 1 day on 6 cm collagen-coated dishes and in
Dulbecco’s modi¢ed Eagle’s medium (DMEM) supplemented with
20% (v/v) fetal calf serum. C2C12 myoblasts were then infected with
AxCAvDys at a multiplicity of infection (moi) of 100 plaque-forming
units (pfu)/cell and growth medium was replaced by di¡erentiation
medium consisting of DMEM and 5% (v/v) horse serum. After
3 days, cells were harvested and suspended in SDS-PAGE lysis bu¡er
(15% SDS, 70 mM Tris-HCl pH 6.8, 5% L-mercaptoethanol, 10 mM
EDTA). 20 Wg/lane of cell lysate was then separated on 5% SDS-
PAGE and electro-transferred to a PVDF membrane (Immobilon,
Millipore). The blot was incubated with the anti-dystrophin monoclo-
nal antibody, DYS2 (Novocastra), at 1/100 dilution. This antibody
recognizes the ¢nal 17 amino acids of human dystrophin. Immune
complexes on the blot were detected with horseradish peroxidase-con-
jugated rabbit anti-mouse IgG1 (Zymed) and the ECL Western blot-
ting detection reagents (Amersham).
2.4. Immunohistochemistry of adenovirus-injected muscles
Prior to in vivo injection, each AxCAvDys stock solution was run
through a CHROMA SPIN column (Clontech) saturated with PBS in
order to eliminate glycerol. 50 Wl puri¢ed AxCAvDys solution was
then directly injected using a 27-gauge needle into the left tibialis
anterior (TA) muscle of mdx mice of 12^16 weeks of age. One week
after infection, the muscle was isolated and then frozen in liquid nitro-
gen-cooled isopentane. Cross-sections (6 Wm) from injected and non-
injected mdx muscles and control C57BL/10 muscle were prepared on
the same slide, dried and ¢xed in acetone for 10 min. Immunohisto-
chemical procedures were carried out using the following antibodies:
a rabbit polyclonal antibody against the C-terminal 25 amino acids of
dystrophin (anti-C, generous gift of Dr. Y. Nonomura), a rabbit poly-
clonal antibody against amino acids 2360^2409 of dystrophin, corre-
sponding to a part of the 19th rod repeat (P23a, obtained from Dr.
M. Yoshida) [26], a sheep polyclonal antibody against L-dystroglycan
[27], a rabbit polyclonal antibody against K-sarcoglycan (obtained
from Dr. Y. Wakayama) [27], and a rabbit polyclonal antibody (gen-
erous gift of Dr. S. Kameya) against amino acids 191^206 of K1-
syntrophin [28]. The primary antibody was detected with either
FITC-conjugated goat anti-rabbit IgG (Tago Immunologicals) or rab-
bit anti-sheep IgG (Organon Teknika). The signals obtained from the
same slide were recorded photographically under the same condition
using the laser scanning confocal imaging system MRC-1000 (Bio-
Rad).
3. Results
3.1. Generation of recombinant adenoviruses encoding
truncated dystrophin
We designed a series of six truncated dystrophins with con-
secutive deletions within the rod domain, as shown in Fig. 1.
Using the six dystrophin cDNAs, we successfully generated
six recombinant adenoviruses. While all constructs retain the
N-terminal actin-binding, cysteine-rich, and C-terminal do-
mains, the designed vDys, AX2, AX11, AH3 or M3 contain
three, three, two and one rod repeat, respectively, as well as
both hinges 1 and 4; and then, the vDysH1 and vDysH4 have
no rod repeats and either hinge 1 or 4, respectively. In cDNAs
for the former four vDys, we reconstructed a putative triple-
helical structure [8] at the fused position of the rod domain
(Fig. 1B). We digested the genome of each propagated Ax-
CAvDys with restriction enzymes and con¢rmed the size of
inserted cDNA (data not shown).
3.2. Adenovirus vector-mediated expression of truncated
dystrophins in a myogenic cell line
To verify the correct transcription and translation of trun-
cated dystrophins after the propagation of their correspond-
ing AxCAvDys, we infected C2C12 myoblasts with each Ax-
CAvDys and performed Western blot analysis. Each vDys
revealed its expected size (Fig. 2, lanes 2^6), but the band
for vDysH4 appeared at a higher position than expected
(103 kDa) (Fig. 2, lane 7). Endogenous dystrophin was not
clearly detected in C2C12 cells because the cells were not fully
di¡erentiated into mature myo¢bers (Fig. 2, lane 1). When the
quantity of each truncated dystrophin was compared,
vDysM3 appeared in the largest amount. These results indi-
cate that recombinant AxCAvDys e¡ectively infect cultured
muscle cells and express truncated dystrophin under the reg-
ulation of the CAG promoter [20]. They also indicate that
vDysM3 protein is most stably expressed in vitro.
3.3. Adenovirus vector-mediated expression of truncated
dystrophins in the skeletal muscle of mdx mice
To determine whether truncated dystrophins are stably ex-
pressed in muscle ¢bers in vivo, we injected recombinant Ax-
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Fig. 2. Ad vector-mediated transfer of truncated dystrophin cDNAs
with varying numbers of rod repeats into the murine myogenic cell
line. C2C12 cells were infected with each recombinant AxCAvDys
at a moi of 100, after which they were induced to di¡erentiate by
changing the culture medium. Three days after infection, the cells
were harvested. The total cell extract (20 Wg/lane) was separated by
SDS-PAGE (5% acrylamide), transferred to PVDF membrane and
incubated with monoclonal antibody DYS2, which acts against the
last 17 amino acids of dystrophin. Lane 1: non-infected C2C12
cells; 2: AxCAvDysAX2; 3: AxCAvDysAX11; 4: AxCAvDy-
sAH3; 5: AxCAvDysM3; 6: AxCAvDysH1; 7: AxCAvDysH4. All
AxCAvDys expressed truncated dystrophin of the expected size, ex-
cept AxCAvDysH4; the product of AxCAvDysH4 migrated more
slowly than estimated (lane 7). MW: molecular weight.
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CAvDys directly into the TA muscle of adult mdx mice and
performed immunohistochemical analyses (Fig. 3). In the Ax-
CAvDys-injected mdx muscles, recombinant Ads evoked a
strong in¢ltration of mononuclear cells and necrosis of muscle
¢bers (data not shown), as previously reported [14]. Dystro-
phin-positive ¢bers had a tendency to appear in a cluster at
the periphery of the damaged area. This is where all truncated
dystrophins, except vDysH1, are expressed at the sarcolem-
ma; they often did so in greater intensity than endogenous
dystrophin in control C57BL/10 mice when both were stained
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Fig. 3. Ad vector-mediated transfer of truncated dystrophin cDNA into the skeletal muscle of dystrophic mdx mice. Recombinant Ad was di-
rectly injected into the TA muscle of adult mdx mice. The dose of vector injected is listed in Table 2. Seven days after injection, mice were
killed and frozen sections of the TA muscle were immunostained for dystrophin using a rabbit polyclonal antibody, anti-C, which recognizes
the carboxy-terminus of dystrophin. B10: adult normal C57BL/10 mouse; mdx : non-injected mdx mouse; AX2, AX11, AH3, M3, H1, and H4:
AxCAvDys-injected mdx mice. Bar = 100 Wm.
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on the same slide. The proportion of dystrophin-positive ¢-
bers is considerably higher than that of revertant ¢bers in mdx
skeletal muscle. In addition, using antibody P23a [26], we also
con¢rmed that dystrophin-positive ¢bers were not revertant
¢bers (data not shown). Though the intensity of dystrophin
immunostaining in AxCAvDys-injected muscles varied from
¢ber to ¢ber, strong immuno£uorescence was consistently ob-
served in AxCAvDysM3-injected muscles. By contrast, the
signal of the dystrophin-positive ¢bers at the sarcolemma
was faint and patchy in AxCAvDysH1-injected muscle.
To evaluate the e¡ectiveness of each vDys in mdx mouse
skeletal muscle, we selected, in each AxCAvDys-injected mdx
muscle, more than three areas where dystrophin-positive ¢bers
formed clusters. Three independent researchers evaluated the
numbers of truncated dystrophin-expressing ¢bers and the
intensity of dystrophin immuno£uorescence and the results
are summarized in Table 2. The results indicate that truncated
dystrophins containing some rod repeats and both hinge 1
and 4 localized e¡ectively at the sarcolemma. The loss of
hinge 4, as demonstrated by vDysH1, results in a great reduc-
tion of the dystrophin’s localization at the sarcolemma.
3.4. Recovery of dystrophin-associated proteins at the
sarcolemma
To evaluate dystrophin’s function as a key molecule for the
formation of the dystrophin-DAP complex, we examined the
expression of DAPs at the sarcolemma of mdx skeletal
muscles after AxCAvDys injection (Fig. 4). In comparison
with the reduced expression of DAPs in mdx skeletal muscle
[29], sarcolemmal expression of DAPs was markedly retrieved
in the dystrophin-positive ¢bers of AxCAvDys-injected
muscles, except AxCAvDysH1-injected muscles. Very interest-
ingly, the intensity of immuno£uorescence for DAPs was ho-
mogeneous irrespective of the levels of dystrophin expression.
In AxCAvDysH1-injected mdx muscle, however, immuno-
£uorescence of DAPs along sarcolemma was di⁄cult to de-
tect. The signals, especially for L-dystroglycan and K-sarcogly-
can in vDysH1-injected muscle, were extremely low in the
majority of dystrophin-positive ¢bers. These results show
that truncated dystrophins, except for vDysH1, can e¡ectively
restore DAPs at the sarcolemma.
4. Discussion
We examined the expression of recombinant Ad constructs
of truncated dystrophins in both cultured skeletal muscle cells
and adult mdx mouse skeletal muscle in vivo. The use of a
combination of a widely infectious Ad vector and the strong
promoter in skeletal muscle, CAG [20,21], enabled us to com-
pare the expression of recombinant truncated dystrophin
cDNAs.
Surprisingly, vDysM3, which has only one rod repeat,
showed the highest expression in vitro. When AxCAvDys
were injected into adult mdx skeletal muscle, vDysM3 was
e¡ectively expressed as well as vDysAX2, AX11, and AH3.
Though the precise protein structure of vDysM3 is currently
not known, we speculate that the vDysM3 molecule might be
stable in the skeletal muscle of adult mice as well as in vitro.
Clemens et al. [30] have generated three truncated dystrophin
constructs with an in-frame deletion (3.0, 4.4 or 5.7 kbp dele-
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Table 2
Quantitative analysis of Ad vector-mediated transfer of truncated dystrophin cDNAs into mdx skeletal muscle
Recombinant adenovirus Dose of virus
(U108 pfu/muscle)
Dystrophin-positive
¢bersa
Intensity of immuno£uorescence
at sarcolemmab
n
mean (range)
AxvDysAX2 8.6 32% (22^39) ++ 4
AxvDysAX11 2.2 27% (11^56) ++ 4
AxvDysAH3 14 33% (15^45) ++ 4
AxvDysM3 16 33% (22^51) +++ 8
AxvDysH1 6.0 12% (3^22) + 3
AxvDysH4 13 21% (16^31) ++ 3
Three regions were selected from each injected muscle and evaluated blind by three independent observers.
aThe percentage of dystrophin-positive ¢bers in the selected regions.
bIntensity of sarcolemmal labeling of dystrophin was evaluated from 0 to +++.
Table 1
DNA sequences of synthetic oligonucleotides used for construction of truncated dystrophin cDNAs
Primer Primer sequence (5P-3P) Sequence position
F1 GCCGGCGAACAACTTAAGGTATTG 1799^1816
2 GCCGGCCTTAAGGAGGTCAATACTGAG 8936^8950
3 TTAAGGTATTGAACACCAGATGGA 1806^1816, 9269^9281
4 GCCGGCCAATTGGGAAGTAAGCTG 1409^1426
5 GGAACATGCATTCAACATCGAA 796^817
6 CAGGAAGTGGAAGCCCACAGGGACTTTGGTCCAG 953^964, 9329^9350
R1 GCCGGCCTCGAGACTTGATAACATTTC 2005^1991
2 GGCGCCTTGACTTTCTCGAGGTGATC 9144^9125
3 AGCTTCCATCTGGTGTTCAATACC 9285^9269, 1816^1810
4 GCCGGCAAGCTTCCATCTTGAATTTAG 1501^1486
5 CGGCAGGGCCTTCTGCAGTCTTCGGTCTTCAGGAGCTTCC 9564^9545, 1189^1174
6 GTCCCTGTGGGCTTCCACTTCCTGGATGGC TTC 9340^9329, 964^944
7 ATCTGCAGGATATCCATGG 9657^9639
Oligonucleotides F3 and R3 were used for direct annealing to form a DNA fragment. The other oligonucleotides were used as primers for the PCR
reaction. Underlines correspond to the sequence of human dystrophin cDNA, GenBank accession number M18533.
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tion) of the rod domain, where 15, 10 or six rod repeats
remained in the ¢nal constructs. These constructs demon-
strated that the amount of dystrophin produced in cultured
myogenic cells is not exclusively determined by the size of the
deletion. Together with our ¢ndings, we can conclude that the
stability of the truncated dystrophin is independent of the
number of rod repeats. These results are consistent with the
observation that the length of the deletion in the dystrophin
gene in BMD patients correlates with neither the amount of
dystrophin produced nor the severity of the disease [9].
Although AxCAvDysH1 and AxCAvDysH4 were injected
in high viral doses, their expression was considerably lower
than that of the other constructs. This is likely because both
vDysH1 and vDysH4 completely lack the rod repeats. In
addition, it must be noted that the expression of vDysH1
was extremely low. vDysH1 lacks hinge 4, an area containing
a WW domain [31] which seems to connect the dystrophin
molecule to the sarcolemmal membrane by binding to the
XPPXY motif of L-dystroglycan [32]. We suggest that
vDysH1 is less stable because of its reduced binding ability
to L-dystroglycan. vDysH4 does not have hinge 1. Although
its missing rod repeat may largely explain its lower stability,
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Fig. 4. Restoration of dystrophin-associated proteins at the sarcolemma in AxCAvDysM3-injected mdx skeletal muscle, but not in AxCAv
DysH1-injected mdx mice. Injections and immunostaining were performed as described in Section 2. The muscle ¢bers successfully expressing
dystrophin in AxCAvDysM3-injected mdx mice were stained intensely with antibodies against L-dystroglycan, K-sarcoglycan, and K1-syntro-
phin. The dystrophin-negative ¢bers, marked with an asterisk, were negative for DAPs. In AxCAvDysH1-injected mdx muscle, the signal for
dystrophin was markedly weak. In such dystrophin-positive ¢bers, DAPs, especially L-dystroglycan and K-sarcoglycan, were not detected at the
sarcolemma. Bar = 50 Wm.
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the lack of hinge 1 could be another contributing factor. Or-
tiz-Lopez et al. [33] identi¢ed a missense mutation in the hinge
1 region of a family of X-linked dilated cardiomyopathy
found in North America, and presumed that the mutation
results in a con¢gurational change in the dystrophin molecule.
Together with our results of retarded migration of vDysH4 in
Western blot, hinge 1 might be critical for conformation of
dystrophin molecule.
As predicted from transgenic studies of mini-dystrophin
cDNA [15], small truncated dystrophins can support the ac-
cumulation of DAPs at the sarcolemma in mdx skeletal
muscle if C-terminal parts of the dystrophin molecule are
intact. Our results demonstrate that a truncated dystrophin
that maintains both hinge 4 and the cysteine-rich domain
can e¡ectively accumulate DAPs at the sarcolemma. Our re-
sults also indicate that high level expression of vDys is not
necessarily required for the full recovery of DAPs, as sug-
gested by previous mini-dystrophin research [15].
It is, however, also important to note that the recovery of
DAPs at the sarcolemma is not su⁄cient for the restoration of
dystrophin function. For example, transgene experiments with
Dp71 cDNA, which encodes one of the dystrophin isoforms
lacking the actin-binding and rod domains, showed complete
recovery of DAPs, but the dystrophic phenotype rather deter-
iorated [34,35]. Furthermore, Chamberlain and colleagues in-
troduced mdx mice with a series of truncated dystrophin
cDNAs as transgenes. They ascertained that a dystrophin
construct which contained hinges 1 and 4 but has no rod
repeats is stably expressed at the sarcolemma, but could not
improve the dystrophic phenotype (personal communication).
Thus, long-term expression of our truncated dystrophins is
required to prove their function in vivo. The Ad vectors we
used evoke strong immune reactions in adult mice and prevent
long-lasting expression of the exogenous gene. Therefore, we
injected AxCAvDysM3 into neonatal mdx mice. Four weeks
after the injection, degeneration of muscle ¢bers decreased
and centrally nucleated ¢bers were almost absent in the Ad-
injected regions (unpublished data). Thus, at present,
vDysM3, containing only one rod repeat and intact N-termi-
nal and C-terminal domains, is the smallest molecule required
to alleviate the dystrophic phenotype. To con¢rm that this
truncated dystrophin does indeed prevent dystrophic change,
we are now generating transgenic mice of vDysM3 cDNA.
In this report we showed that the truncated dystrophins,
vDysAX2, AX11, AH3, and M3, reveal a high e⁄ciency of
expression in adult mdx skeletal muscle. New vectors which
evoke fewer immune reactions and allow long-standing ex-
pression of the transferred gene are under active consideration
in the gene therapy of DMD. The AAV vector, which is one
of them, has several attractive features including targeted in-
tegrating capacity, but only allows the insertion of up to 4.6
kbp of exogenous DNA fragment [17]. Accordingly, even the
6.3 kbp mini-dystrophin cDNA is too long to be inserted into
AAV vectors. Our truncated dystrophin cDNAs, especially
the 3.7 kbp cDNA for vDysM3, can be a good candidate
to be inserted into AAV vectors.
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